James E. Flynn, 10% Owner at Aclaris Therapeutics, Inc. (ACRS), sold 1,056,620 shares at $6.16 ($6.5M) on 2019-05-09, disclosed to the SEC on 2019-05-13.
Open-market sale of $6.5M ACRS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.16 | 172,800 | $1.1M | 16.5% |
| 2 | $6.16 | 261,345 | $1.6M | 24.9% |
| 3 | $6.16 | 261,345 | $1.6M | 24.9% |
| 4 | $6.05 | 71,869 | $435K | 6.7% |
| 5 | $6.05 | 108,696 | $658K | 10.2% |
| 6 | $6.05 | 108,696 |
| $658K |
| 10.2% |
| 7 | $6.05 | 71,869 | $435K | 6.7% |
| Total | $6.12 avg | 1,056,620 | $6.5M | 100% |
| Filing → |
| SPRY | SELL | 2025-07-01 | $27.3M | — | Filing → |
| ONCR | SELL | 2022-12-30 | $65K | — | Filing → |
| ONCR | SELL | 2022-12-21 | $23K | — | Filing → |